Drug-coated Balloon Catheter Market

North America is the largest regional market for drug-coated balloon catheters. The region is the forefront of medical research and technological advancements. The region boasts a robust healthcare infrastructure with well-established catheterization labs and experienced interventional cardiologists.

The market for drug-coated balloon catheters is projected to reach the billion-dollar mark in revenue by the end of 2030.

Drug-coated balloon catheters are commonly used for treating various cardiovascular conditions, such as coronary and peripheral artery disease, often requiring specialised interventions.

Peripheral vascular disease (PVD) is the dominant market segment. Drug-coated balloon catheters have emerged as a promising treatment option for PVD as they offer targeted drug delivery to the affected arterial walls during angioplasty procedures. The use of drug-coated balloon catheters in PVD cases has demonstrated reduced rates of restenosis and improved clinical outcomes, driving their widespread adoption in this patient population.

Bayer AG, Medtronic plc, B. Braun SE, Koninklijke Philips N.V., Biosensors International Group, Boston Scientific Corporation, and BIOTRONIK constitute some of the major players in the worldwide market for drug-coated balloon catheters.